Microbot Medical (MBOT) just unveiled an announcement.
Microbot Medical Inc. has announced Brigham and Women’s Hospital as a new clinical trial site for its LIBERTY® Endovascular Robotic Surgical System, marking a significant milestone in the device’s development. The hospital’s clinical staff has been trained and received the investigational units, setting the stage for the trial’s progress. While this news is promising, the company cautions investors with forward-looking statements, emphasizing that actual results may vary and advising them to consult regulatory filings for a comprehensive risk assessment.
See more insights into MBOT stock on TipRanks’ Stock Analysis page.
